Teva Says B-R Combo Superior Patient Outcomes vs Standard

Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care Five sets of new data analyses presented this week at the 54 th annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, show that a first-line treatment regimen of bendamustine plus rituximab (B-R) results in superior patient outcomes compared with current standard of care, CHOP-R/CVP-R, in patients with indolent non-Hodgkin lymphomas (iNHL) and mantle cell lymphomas (MCL). [1] , [2] , [3] , [4] , [5] A sub-analysis of the StiL NHL 1-2003 Study, demonstrated significantly prolonged progression free survival (PFS) and overall survival (OS) for iNHL and MCL patients who achieved a complete response (CR) compared with a partial response (PR), irrespective of whether they received B-R or CHOP-R treatment. [ 1 ] A CR was observed in a higher proportion of patients treated with B-R (39.8%) vs. those treated with CHOP-R (30.0%). [ 1 ]